Brief Communication

Neonatal extracorporeal membrane oxygenation: A case report and current state in Mainland China

Jianguo Zhou, Chao Chen, Guoping Lu¹, Yun Cao

Abstract

We report the first successful treatment of extracorporeal membrane oxygenation (ECMO) in a neonate with Group B streptococcus (GBS) sepsis and cardiorespiratory failure, and further conduct a literature review in the experience of neonatal ECMO utility in Mainland China. A term neonate with cardiorespiratory failure secondary to GBS sepsis was put on venous-arterial ECMO at 23 h of age. After 273 h of ECMO running, the patient was saved and without major complications. The comprehensive literature review demonstrated that there were 22 neonates received ECMO previously in Mainland China, 14 of 22 of the patients are cases with congenital heart defects. The overall survival rate was 41% (9/22). Neonatal ECMO was underdeveloped in Mainland China. Moreover, it does provide a chance of survival for neonates who have a grave prognosis by conventional treatment.

Keywords: Extracorporeal membrane oxygenation, Group B streptococcus, Mainland China, neonate

Introduction

Extracorporeal membrane oxygenation (ECMO) is an essential part of life support and acts as the last resort for severe cardiorespiratory failure neonates without response to aggressive conventional treatment. ECMO improves oxygenation and organ perfusion and saves precious time for failed heart and lung to recover.¹ Venous-venous ECMO and Venous-Arterial ECMO are two most common ECMO modes.² Since the first case of successful neonatal ECMO for a severe meconium aspiration syndrome (MAS) neonate in 1976, ECMO has been used and saved thousands of neonates suffering from respiratory and/or cardiac failure world widely.³ The most common candidate diseases for neonatal ECMO are MAS, persistent pulmonary hypertension of neonate, congenital diaphragmatic hernia, severe sepsis, etc.⁴ Neonatal ECMO is still at the underdeveloped stage in Mainland China, in comparison with other countries. The current paper reported the first neonate with early-onset Group B streptococcus (GBS) sepsis saved by V-A ECMO in Mainland China, and we also conducted a comprehensive literature review of neonatal ECMO utility in Mainland China.

Case Report

A term neonate with gestational age of 39 weeks and birth weight of 3180 g was born by spontaneous vaginal delivery with unremarkable maternal history; however, the GBS status was unknown. She did not need aggressive resuscitation in the delivery room, had good Apgar score of 10 and 10 at 1 and 5 min, respectively. Initially, she was sent to the nursery and cared by parents. Eight hours later, she developed respiratory distress and needed to be intubated and received mechanical respiratory support; the antibiotics were also started empirically after blood
culture sampling. Moreover, the chest X-ray showed right lung infiltration. She was transported to our Neonate Intensive Care Unit (NICU) at the age of 15 h.

In NICU, she developed cardiac and respiratory failure with hypotension and hypoxemia, even though she received an aggressive fluid replacement and inotropic agents including epinephrine and large dose of dopamine. She was put on high-frequency oscillatory ventilation with high mean airway pressure of 17 cmH2O, and high FiO2 of 1.0, she was given inhaled Nitric oxide as well due to pulmonary hypertension confirmed by bedside echocardiography. However, the blood gas was poor as following: pH 7.24, PaO2 35.5 mmHg, PaCO2 40.8 mmHg, and base deficit −9.0 mmol/L. The oxygenation index (OI = MAP × FiO2/ PaO2) was 45. After ruling out neonatal ECMO contraindications of intracranial hemorrhage, unreparable congenital heart defects (CHDs), she was put on V-A ECMO at the age of 23 h. In addition, the blood culture sent in referral hospital reported after was positive for GBS and confirmed the diagnosis of early onset GBS sepsis complicated by cardiorespiratory failure with no response to maximal conventional treatment.

Medtronic Minimax Plus oxygenator and Bio-console 560 Centrifugal blood pump was used in this patient. The V-A ECMO cannulation was achieved by right jugular vein and common carotid artery insertion. The positions of the catheters were guided by bedside ECHO. During the 273 h ECMO procedure, the blood gas, lactate level, and glucose level were monitored every 2 h, C-reactive protein, and chest X-ray was done daily. The ECMO flow was maintained at 100–130 ml/kg/min based on hemodynamic monitoring.

She tolerated ECMO well without major complications, apart from mild bleeding at the sites of cannulation, thrombocytopenia, etc. And, she was decannulated at the age of 12 days after 273 h ECMO and extubated the day after. Neurologic evaluations including cranial magnetic resonance imaging and electroencephalogram were normal before discharge at the age of 36 days.

**Discussion**

Until July 2015, there were totally 69,114 patients registered in the Extracorporeal Life Support Organization (ELSO) received ECMO treatment worldwide based on the data of ELSO. And, more than half of the cases were neonatal cases which consisted 51.4% (35505/69114) of all, and the survive rate were 74% and 41% in respiratory failure and cardiac failure cases, respectively.[5] In comparison with the advanced and sophisticated ECMO utility in critical patients in developed countries, the ECMO utility was still at the underdeveloped stage, especially neonatal ECMO, in Mainland China. And, survive rate remains much lower than developed countries.

To know the current state of neonatal ECMO in Mainland, China, we conducted a comprehensive literature review through searching “neonatal ECMO” in Chinese databases, including China Knowledge Resource Integrated Database and Wanfang database; we also used the keywords of “(ECMO) AND CHINA [Affiliation]” as searching strategy in PubMed for papers published by authors from mainland, China. Finally, 176 papers were retrieved from Chinese databases and PubMed. After abstract reviewing, 8 papers were recruited in the full paper assessment. Based on the clinical information, we deleted duplicated cases from the same institutions. After that, we collected 22 reported neonatal cases with the birth weight of 2.8–4.0 kg. The clinical characteristics were demonstrated in Table 1.[6-12] Fourteen of the 22 patients were patients with CHDs, while the other 8 patients were non-CHD patients, including one MAS, 4 neonatal respiratory distress syndrome (NRDS), 2 pulmonay dysplasia, 1 cardiac arrest secondary to hydronephrosis and electrolytes disturbance. V-A ECMO was utilized in 21 of 22 patients; the duration of ECMO running was 64 ± 42 h (range from 7 to 173 h). Complications occurred in 13 patients, and the survive rate was 41% (9/22). Of note, the survive rate in non-CHD patients was only 25% (2/8), and none of the patients with congenital anomalies, such as pulmonary dysplasia and hydronephrosis survived. The current case is the first neonate case with severe GBS sepsis saved by V-A ECMO in Mainland, China.

In this article, we reported the first neonatal ECMO for GBS sepsis neonate in Mainland China, and the ECMO duration of 273 h was the longest among all reported cases. Among 22 reported neonatal ECMO cases in previous papers, there were only 2 non-CHD patients survived. The ECMO running durations in our case were much longer than the 48 h in the MAS case and 50 h in the NRDS case. According to the available evidence, GBS could cause a severe inflammatory reaction in the patients, which is also manifested in our case by extremely elevated C-reactive protein levels. This kind of inflammation recovers much slower than the self-limited lung diseases such as MAS and NRDS. That could be the underlying reason for a long duration of ECMO running in our case. Of note, because of low survive rate in patients with pulmonary dysplasia;
the administration of neonatal ECMO in such patients should be cautious.

In Mainland China, the first reported Neonatal ECMO case was a patient with left hypoplastic heart in 2006, and the first reported non-CHD case was a neonate with MAS in 2009. The previous 22 cases reported by Chinese authors were done only by big hospitals located in Beijing, Shanghai, Hangzhou, and Guangdong, these 4 megacities with the highest economical level in Mainland China. The high fee of ECMO not covered by Chinese Medicare is the biggest hurdle for developing neonatal ECMO in China.

**Conclusion**

The neonatal ECMO was still underdeveloped in Mainland China; however, because of the remarkable effectiveness of ECMO in treating critical patients without response to conventional treatment, ECMO does provide a chance of survival for neonates who have a grave prognosis by conventional treatment.

**Acknowledgment**

The authors would like to acknowledge the support of Denny John, Tutor, People’s Open Access Education Initiative, Manchester, United Kingdom for the review of language and the statistical calculations in the manuscript.

---

**Table 1: Reported neonatal ECMO cases done in Mainland, China**

| First author (year) | Age (year) | Gender | BW/GA (kg/Weeks) | Diagnosis | ECMO mode | Duration(h) | Complications | Survive (Yes/No) |
|---------------------|------------|--------|-------------------|-----------|-----------|-------------|---------------|-----------------|
| Zhao J, 2006[6]     | 5d         | Female | 4/−               | left hypoplastic heart | V-A       | 146         | Renal failure, infection | No              |
| He XJ, 2009[7]      | 6d         | Male   | 2.8/40            | TGA + ASD + PDA        | V-A       | 87          | Bleeding, cardiac tamponade, hemolysis | No              |
| Fu WD, 2011[8]      | 18d        | Male   | 3.4/−             | TGA/IVS, pulmonary hemorrhage | V-A       | 63          | Bleeding, DIC | No              |
| Lin R, 2012[9]      | 19d        | Male   | 4.0/−             | TGA            | V-V        | 15          | DIC, MODS      | No              |
| Zheng ML, 2013[10]  | 33h        | Male   | 42/−              | MAS               | V-A       | 48          | Hypertension, thrombocytopenia | Yes             |
| Hong XY, 2013[11]   | 13d        | Male   | 3.3/−             | TGA + IVS + PDA     | V-A       | 96          | Oxygenator leaking | Yes             |
| Current case        | 23h        | Female | 3.2/39+6          | GBS               | V-A       | 275         | Hemolysis, thrombocytopenia | Yes             |

TGA: Transposition of the great arteries; ASD: Atrial septal defect; PDA: Patent ductus arteriosus; IVS: Intact ventricular septum; DIC: Disseminated intravascular coagulation; MODS: Multiple organ dysfunction syndrome; TAPVC: Total anomalous pulmonary venous connection; IAA: Interrupted aortic arch; CoA: Coarctation of the aorta

---

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Rehder KJ, Turner DA, Cheifetz IM. Extracorporeal membrane oxygenation for neonatal and pediatric respiratory failure: An evidence-based review of the past decade (2002-2012). Pediatr Crit Care Med 2013;14:851‑61.
2. Rais-Bahrami K, Van Meurs KP. Venoarterial versus venovenous ECMO for neonatal respiratory failure. Semin Perinatol 2014;38:71‑7.
3. Bartlett RH, Harken DE. Instrumentation for cardiopulmonary bypass – Past, present, and future. Med Instrum 1976;10:119‑4.
4. Roy BJ, Rycus P, Conrad SA, Clark RH. The changing demographics of neonatal extracorporeal membrane oxygenation patients reported to the Extracorporeal Life Support Organization (ELSO) Registry. Pediatrics 2000;106:1334‑8.
5. Extracorporeal Life Support Organization. Available from: https://www.elso.org/Registry/Statistics/InternationalSummary.aspx. [Last accessed on 2015 Sep 17].
6. Zhao J, Liu JP, Feng ZY, Hei FL, Hu SS, Lin YL, et al. Clinical outcomes and experience of 12 postoperative cardiac surgical children managed with extracorporeal membrane oxygenation. Chin Pediatr Emerg Med 2006;13:417‑20.
7. He XJ, Tan LH, Lin R, Zhang ZW, Du LZ. ECMO in a neonate with low postoperative cardiac output. Chin J Thorac Cardiovasc Surg 2009;25:48‑9.
8. Fu WD, Zhang W, Wang W, Jiang L, Shen J, Tang JZ, et al. A case series of 8 children supported with extracorporeal membrane oxygenation. Chin J Thorac Cardiovasc Surg 2011;27:14‑6.
9. Lin R, Zhang CM, Tan LH, Shi LP, Xiong QX, Zhang EW,
et al. Emergency use of extracorporeal membrane oxygenation in pediatric critically ill patients. Zhonghua Er Ke Za Zhi 2012;50:649-52.

10. Zheng ML, He SR, Liu YM, Zhou CB, Sun YX, Sun X, et al. A case report and review of extracorporeal membrane oxygenation treatment of intensive meconium aspiration syndrome. South China J Cardiovasc Dis 2013;11:165-8.

11. Hong XY, Zhou GX, Liu YH, Liu YY, Gao HT, Wang H, et al. Mechanical circulatory support in resuscitation of pediatric patients with complex congenital heart defects committed with acute heart arrest: 4 cases report. Chin J Extracorpor Circ 2013;11:165-8.

12. Hong XY, Zhou GX, Liu YH, Liu YY, Wang H, Gao HT, et al. Application of extracorporeal membrane oxygenation in pediatric cardiopulmonary failure. J Clin Pediatr 2015;33:5-8.